Comparative Pharmacology
Head-to-head clinical analysis: COLESEVELAM HYDROCHLORIDE versus LOCHOLEST LIGHT.
Head-to-head clinical analysis: COLESEVELAM HYDROCHLORIDE versus LOCHOLEST LIGHT.
COLESEVELAM HYDROCHLORIDE vs LOCHOLEST LIGHT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Colesevelam hydrochloride is a bile acid sequestrant that binds bile acids in the intestine, forming an insoluble complex excreted in feces. This reduces enterohepatic circulation of bile acids, leading to increased conversion of cholesterol to bile acids in the liver and upregulation of LDL receptors, resulting in decreased serum LDL cholesterol. In diabetes, it improves glycemic control possibly by altering bile acid signaling via FXR and TGR5 receptors, affecting hepatic glucose production and incretin release.
Locholest Light is a bile acid sequestrant that binds bile acids in the intestine, forming an insoluble complex that is excreted in feces. This reduces enterohepatic circulation of bile acids, leading to increased conversion of cholesterol to bile acids in the liver and decreased serum LDL cholesterol.
3.75 g orally once daily or divided as 1.875 g twice daily with meals and liquid; maximum 4.375 g/day.
LOCHOLEST LIGHT is not a recognized drug name. No data available.
None Documented
None Documented
Not applicable as colesevelam is not absorbed; it acts locally in the gastrointestinal tract.
Terminal elimination half-life is approximately 19-24 hours; due to enterohepatic recirculation, effective half-life may be extended. Steady state is achieved within 4-6 weeks with continuous dosing.
Colesevelam is not absorbed systemically; it is excreted unchanged in the feces via biliary elimination. No renal excretion occurs.
Primarily biliary/fecal (approximately 75% as metabolites, <10% unchanged drug in feces); renal excretion accounts for about 20% of total elimination (mainly as inactive metabolites).
Category A/B
Category C
Bile Acid Sequestrant
Bile Acid Sequestrant